Displaying 132 (all) recruiting clinical trials.
-
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-na ve EGFR-mutant Locally Advanced or Metastatic NSCLC
The purpose of this study is to find out whether the addition of ramucirumab to osimertinib is better at controlling EGFR lung cancer than just ...Phase
Interventional
-
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
ACNS1833 is a prospective randomized phase 3 study comparing selumetinib to CV in previously untreated LGG not associated with neurofibromatosis or BRAFV600E. This non-inferiority study ...Phase
Interventional
-
A Multicenter Clinical Trial of Intravesical Bacillus Calmetter-Guerin (BCG) in combination with ALT-803 in Patients with BCG Unresponsive High Grade non-Muscle Invasive Bladder Cancer
The purpose of the study is to assess effectiveness and safety of the intravesical BCG (Bacillus Calmetter-Guerin) in combination with ALT-803 in patients with BCG ...Phase
Interventional
-
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1(NF1)
The purpose of the study is to find out the safety and efficacy of the drug selumetinib in treating patients with low-grade glioma. We want ...Phase
Interventional
-
First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
The purpose of the study is to determine the safety of GEN1046 in patients with malignant solid tumors. GEN1046 is investigational drug in this study ...Phase
Interventional
-
A Phase 1/2a Open-Label Multi-Center Trial to Assess Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of CLN-081 in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
The purpose of the study is to look at safety and tolerability of orally administered CLN-081 monotherapy, as single dose and after multiple doses over ...Phase
Interventional
-
A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas Cutaneous Squamous Cell Carcinoma Merkel Cell Carcinoma and Other Rare Skin Tumors
The purpose of the study is to determine the safety and efficacy of talimogene laherparepvec monotherapy followed by combination therapy with nivolumab (NIVO) for patients ...Phase
Interventional
-
MULTICENTER PHASE II NEOADJUVANT AND ADJUVANT STUDY OF ALECTINIB ENTRECTINIB OR VEMURAFENIB PLUS COBIMETINIB IN PATIENTS WITH STAGES I-III NON-SMALL CELL LUNG CANCER WITH ALK ROS1 NTRK OR BRAF V600E MOLECULAR ALTERATIONS
The purpose of the trial is to determine the efficacy and safety of drugs in patients with untreated non-small cell lung cancer (NSCLC) tumors. In ...Phase
Interventional
-
A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
The purpose of the study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia ...Phase
Interventional
-
Site for EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
The purpose of the study is to determine the safety and tolerability of pre-operative therapy with 12 weeks of taxane, trastuzumab (or FDA approved biosimilar ...Phase
Interventional
